Warfarin

"Warfarin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.

Descriptor ID	D014859
MeSH Number(s)	D03.383.663.283.446.520.914 D03.633.100.150.446.520.914
Concept/Terms	Warfarin Warfarin 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one Apo-Warfarin Apo-Warfarin Aldocumar Aldocumar Gen-Warfarin Gen-Warfarin Warfant Warfant Coumadin Coumadin Marevan Warfarin Potassium Warfarin Potassium Potassium, Warfarin Warfarin Sodium Warfarin Sodium Sodium, Warfarin Coumadine Coumadine Tedicumar Tedicumar

Below are MeSH descriptors whose meaning is more general than "Warfarin".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Pyrans [D03.383.663]
Benzopyrans [D03.383.663.283]
Coumarins [D03.383.663.283.446]
4-Hydroxycoumarins [D03.383.663.283.446.520]
Warfarin [D03.383.663.283.446.520.914]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 2-Ring [D03.633.100]
Benzopyrans [D03.633.100.150]
Coumarins [D03.633.100.150.446]
4-Hydroxycoumarins [D03.633.100.150.446.520]
Warfarin [D03.633.100.150.446.520.914]

Below are MeSH descriptors whose meaning is related to "Warfarin".

Below are MeSH descriptors whose meaning is more specific than "Warfarin".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Warfarin" by people in this website by year, and whether "Warfarin" was a major or minor topic of these publications.

Bar chart showing 51 publications over 21 distinct years, with a maximum of 5 publications in 2012 and 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	0	1	1
2002	1	0	1
2003	1	1	2
2004	1	0	1
2008	1	1	2
2009	2	1	3
2010	2	2	4
2011	1	0	1
2012	5	0	5
2013	4	1	5
2014	3	0	3
2015	3	0	3
2016	4	0	4
2017	1	1	2
2018	4	0	4
2019	1	0	1
2020	3	0	3
2021	0	1	1
2022	1	0	1
2023	1	2	3
2024	1	0	1

Below are the most recent publications written about "Warfarin" by people in Profiles.

Albaeni A, Li S, Shan Y, Thakker R, Gaalema DE, Saxena R, Kuo YF, Jneid H, Goodwin J. Outcomes Associated With Novel Oral Anticoagulants and Warfarin in Patients With Cardiac Thrombus Following ST-Segment Elevation Myocardial Infarction. Am J Cardiol. 2025 Feb 01; 236:72-78.

View in: PubMed
Rodr?guez-Fern?ndez K, Reynaldo-Fern?ndez G, Reyes-Gonz?lez S, de Las Barreras C, Rodr?guez-Vera L, Vlaar C, Monbaliu JM, Stelzer T, Duconge J, Mangas-Sanjuan V. New insights into the role of VKORC1 polymorphisms for optimal warfarin dose selection in Caribbean Hispanic patients through an external validation of a population PK/PD model. Biomed Pharmacother. 2024 Jan; 170:115977.

View in: PubMed
Sahl?n AO, Jiang H, Lau YH, Cuenza L, Cader FA, Al-Omary M, Surunchupakorn P, Ho KH, Sung J, Lee D, Honda S, Tan Wei Chieh J, Yap J. Direct Oral Anticoagulation Versus Warfarin in Left Ventricular Thrombus: Pooled Analysis of Randomized Controlled Trials. J Clin Pharmacol. 2023 10; 63(10):1101-1107.

View in: PubMed
Lee HJ, Kim HK, Kim BS, Han KD, Park CS, Rhee TM, Park JB, Lee H, Kim YJ. Safety and effectiveness of anticoagulation with non-vitamin K antagonist oral anticoagulants and warfarin in patients on tuberculosis treatment. Sci Rep. 2023 02 04; 13(1):2060.

View in: PubMed
Steiner HE, Carrion KC, Giles JB, Lima AR, Yee K, Sun X, Cavallari LH, Perera MA, Duconge J, Karnes JH. Local Ancestry-Informed Candidate Pathway Analysis of Warfarin Stable Dose in Latino Populations. Clin Pharmacol Ther. 2023 03; 113(3):680-691.

View in: PubMed
Lee HJ, Kim HK, Kim BS, Han KD, Park JB, Lee H, Lee SP, Kim YJ. Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy. PLoS One. 2021; 16(6):e0253310.

View in: PubMed
El Rouby N, Rodrigues Marcatto L, Claudio K, Camargo Tavares L, Steiner H, Botton MR, Lubitz SA, Fallon EN, Yee K, Kaye J, Scott SA, Karnes J, Caleb Junior de Lima Santos P, Duconge J, Cavallari LH. Multi-site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos. Clin Transl Sci. 2021 01; 14(1):268-276.

View in: PubMed
Reyes-Gonz?lez S, de Las Barreras C, Reynaldo G, Rodr?guez-Vera L, Vlaar C, Mejias VL, Monbaliu JM, Stelzer T, Mangas V, Duconge J. Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. Drug Metab Pers Ther. 2020 08 18; 35(4).

View in: PubMed
Asiimwe IG, Zhang EJ, Osanlou R, Krause A, Dillon C, Suarez-Kurtz G, Zhang H, Perini JA, Renta JY, Duconge J, Cavallari LH, Marcatto LR, Beasly MT, Perera MA, Limdi NA, Santos PCJL, Kimmel SE, Lubitz SA, Scott SA, Kawai VK, Jorgensen AL, Pirmohamed M. Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis. Clin Pharmacol Ther. 2020 06; 107(6):1420-1433.

View in: PubMed
Claudio-Campos K, Moner?-Paredes M, Hern?ndez E, Renta J, Duconge J. Low-frequency variants at the CYP2C9 locus among Puerto Rican patients on warfarin: in silico predictions of functionality and conservation. Pharmacogenomics. 2019 08; 20(12):891-902.

View in: PubMed

People

Explore

Similar Concepts

Top Journals